Larimar Therapeutics (LRMR) Non-Current Deferred Tax Liability (2022 - 2023)
Larimar Therapeutics (LRMR) posted Non-Current Deferred Tax Liability of $768000.0 for Q4 2023, down 4.12% on a QoQ basis from $801000.0 in Q4 2022, and down 4.12% year-over-year from $801000.0 in Q4 2022.
Larimar Therapeutics (LRMR) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
Larimar Therapeutics' Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $768000.0 for Q4 2023.
- Quarterly Non-Current Deferred Tax Liability fell 4.12% year-over-year to $768000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $768000.0 (down 4.12% YoY) and the FY2023 annual result came in at $768000.0, down 4.12% from the prior year.
- Non-Current Deferred Tax Liability was $768000.0 for Q4 2023 at Larimar Therapeutics, down from $801000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $801000.0 in Q4 2022 and bottomed at $768000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 768,000.00 |
| Dec 31, 2023 | 768,000.00 |
| Dec 31, 2022 | 801,000.00 |
| Dec 31, 2022 | 801,000.00 |